Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Cerebrovascular Control in Metabolic Syndrome
NCT02936687Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2017
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of NG-monomethyl-L-arginine and ambrisentan in metabolic syndrome (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Change in cerebrovascular blood flow in response to NOS inhibition and Change in cerebrovascular blood flow in response to ET-1 inhibition. Started Jan 2017; status: completed.
02
Drugs
NG-monomethyl-L-arginineambrisentan
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT02936687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936687.